Arovella Therapeutics Limited

ALA

AU0000182784

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 12:10:04 2024-12-04 am EST			5-day change	1st Jan Change
0.1750 ^AUD	-5.41%		-5.41%	+52.17%

Oct. 16	Arovella Therapeutics Limited announced that it has received AUD 0.27 million in funding	CI
Oct. 15	Arovella Therapeutics Forms Clinical Advisory Board to Advise on US FDA Filing	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Arovella Therapeutics Limited

Arovella Therapeutics Limited announced that it has received AUD 0.27 million in funding	Oct. 15	CI
Arovella Therapeutics Forms Clinical Advisory Board to Advise on US FDA Filing	Oct. 14	MT
Arovella Therapeutics Limited Announces Establishment of Clinical Advisory Board	Oct. 13	CI
Arovella Therapeutics Limited(ASX:ALA) added to S&P/ASX Emerging Companies Index	Sep. 22	CI
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2024	Aug. 21	CI
Arovella Therapeutics Limited Auditor Raises 'Going Concern' Doubt	Aug. 20	CI
Arovella Therapeutics Receives Positive Feedback From US FDA for Blood Cancer Treatment; Shares Jump 7%	Aug. 06	MT
Arovella Therapeutics Limited announced a financing transaction	Jul. 03	CI
Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement	Jun. 12	MT
Arovella Therapeutics Completes Process Development for ALA-101 Manufacturing; Shares Jump 9%	Jun. 04	MT
Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	Mar. 25	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	Mar. 19	MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Arovella Boosts Solid Tumor Pipeline with Novel CAR-iNKT Cell Armouring Tech License	Jan. 30	MT
Arovella Therapeutics Manufactures GMP-Grade Lentiviral Vector for Cancer Therapy Product; Shares Climb 4%	Jan. 01	MT
Arovella Therapeutics Ltd. Announces Change of Company Address	Dec. 06	CI
Arovella Therapeutics Appoints CFO	Dec. 01	MT
Arovella Therapeutics Limited Announces Changes to its Board	Nov. 30	CI
Arovella Therapeutics Limited Announces Executive Changes	Nov. 30	CI
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023	Nov. 20	MT
Australian Shares Flat With Positive Bias Amid Hopes of US Fed Keeping Rates Steady	23-10-12	MT
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6%	23-10-11	MT
Arovella Therapeutics Limited Announces Retirement of David Simmonds as Non-Executive Director	23-09-06	CI
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Arovella Therapeutics Raises AU$2.2 Million From Oversubscribed Share Purchase Plan	23-07-11	MT

Chart Arovella Therapeutics Limited

Duration

Period

ALA: Dynamic Chart

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-02-25 - Q2 2025 Earnings Release (Projected)

More about the company